Prevalence and characteristics of hepatitis C virus coinfection in a human immunodeficiency virus clinical trials group: the Terry Beirn Community Programs for Clinical Research on AIDS.
The baseline prevalence of hepatitis C virus (HCV) and human immunodeficiency virus (HIV) coinfection among 2705 patients enrolled in HIV clinical trials in the Community Programs for Clinical Research on AIDS (CPCRA) was 16.6%. For men, multivariate logistic regression showed that the baseline prevalence of HIV-HCV coinfection was positively associated with history of injection drug use, older age, antiretroviral therapy naive status, African American or Latino ethnicity, and no history of having sex with men. No association was found with baseline CD4+ cell count or HIV RNA level. The prevalence of HCV coinfection in a diverse HIV clinical trials cohort provides additional information about risk behaviors and demographic factors that can be used in the analysis of clinical and virologic outcomes.
Tedaldi
Ellen M
EM
Temple University School of Medicine, Philadelphia, Pennsylvania, USA. etedaldi@temple.edu
Hullsiek
Katherine Huppler
KH
Malvestutto
Carlos D
CD
Arduino
Roberto C
RC
Fisher
Evelyn J
EJ
Gaglio
Paul J
PJ
Jenny-Avital
Elizabeth R
ER
McGowan
Joseph P
JP
Perez
George
G
D000328:Adult; D018791:CD4 Lymphocyte Count; D002986:Clinical Trials as Topic; D015331:Cohort Studies; D005260:Female; D006678:HIV; D015658:HIV Infections / Q000150:complications* / Q000276:immunology; D016174:Hepacivirus; D006526:Hepatitis C / Q000150:complications* / Q000453:epidemiology; D006801:Humans; D008297:Male; D015999:Multivariate Analysis; D015995:Prevalence